Healthcare Triangle, Inc. has taken decisive action to comply with Nasdaq's listing requirements by executing a one-for-twenty reverse stock split. This strategic move, effective October 26, 2026, aims to bring the company's stock price above the $1.00 minimum bid price mandated by Nasdaq. The reverse stock split reduces the total number of outstanding shares from 17,730,008 to 886,587 while maintaining the trading symbol 'HCTI.'

The reverse split is part of Healthcare Triangle's broader strategy to regain compliance with Nasdaq's continued listing standards after receiving a delisting determination. This action reflects the challenges many companies face in the competitive landscape of the computer integrated systems design industry.

Background

Healthcare Triangle, Inc., incorporated in Delaware, operates in the Services-Computer Integrated Systems Design sector, as classified under SIC 7373. The company trades on the Nasdaq under the ticker symbol HCTI. Recent filings indicate the company is categorized as an emerging growth company.

What the Filing Says

According to the recent SEC filing (accession number 0001213900-26-112972), the reverse stock split was intended to help the company meet Nasdaq's listing requirements. The filing states, "The Reverse Stock Split was intended to bring the Company into compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market." This action is crucial as the company prepares for a hearing scheduled for November 5, 2026, to appeal the delisting determination.

Impact

The reverse stock split may significantly impact existing shareholders by consolidating their shares, which could alter their perceived ownership stake in the company. However, it does not change the overall percentage of ownership for stockholders, except for fractional shares that were rounded up. This move also affects the company's outstanding warrants, stock options, and convertible securities, which have been adjusted accordingly.

What's Next

The company is scheduled to present its case to the Nasdaq Hearings Panel on November 5, 2026. The outcome of this hearing will determine whether Healthcare Triangle can maintain its listing on the exchange.